[3]Oliveira M, Falato C, Cejalvo JM, et al. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. Ann Oncol. 2023;34(8):670-680. doi:10.1016/j.annonc....
Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers 来自 Semantic Scholar 喜欢 0 阅读量: 35 作者: B. Sousa and F. Cardoso* 摘要: Neoadjuvant therapy (NT) has become a valuable research tool for the incorporation of alternative cytotoxic agents, as well as new biological...
in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet, 2010, 375(9712):377-384.
对于晚期 HER-2 阴性胃癌的一线治疗，其治疗策略仍待进一步探索。一方面，胃癌作为一种高度异质性的肿瘤，需要进一步的研究来确定哪些患者可以从免疫治疗中获益；另一方面，对比其他恶性肿瘤，对于 HER-2 阴性胃癌治疗的探索相对较晚[12]。希望在不久的将来HER-2 阴性胃癌一线治疗方案不再拥有大片的空白。【患者招募】...
[3]Oliveira M, Falato C, Cejalvo JM, et al. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3pr...
O-23. Neoadjuvant letrozole is equally effective in Her 2 positive and negative breast cancersdoi:10.1016/S1359-6349(05)80023-0European Journal of Cancer Supplements
Colorectal cancer patients with HER-2 positive exhibited higher five year survival rate (77.7% vs 61.4%) than HER-2 negative patients but there was no statistical significance. In general, there was also no correlation between HER-2 overexpression and survival time. Part 2: By FISH analysis, ...
She'lldowellinwhichevercareershechoosesbecauseofherpositiveattitude. 在这个句子中,需要选择一个形容词来描述她的态度,以解释为什么她会在任何职业中都做得很好。根据句意,"negative"(消极的)与句中的积极含义相矛盾,因为消极的态度通常不会帮助一个人在任何领域取得成功。而"positive"(积极的)则与句意相符,表示她...
1个有效反应,2个部分反应。 肿瘤发生与反复转移国际数据库描述: Amplification and overexpression of the HER-2 oncogene in breast cancer is felt to be stable over the course of disease and concordant between primary tumor and metastases. Therefore, patients with HER-2-negative primary tumors rarely ...
A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high-risk features and poor outcome. A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with...